Effects of camelina oil supplementation on lipid profile and glycemic control: a systematic review and dose‒response meta-analysis of randomized clinical trials

Table 3 Summery effects of Camelina oil on cardiovascular risk factors

Outcomes (unit)	Effect sizes (N)	Participants (n)		WMD (95% CI)^a	P-*value*	I^{2 b} (%)	P^c _{heterogeneity}	Egger
Outcomes (unit)	Effect sizes (N)	Camelina oil	Placebo	WMD (95% CI)^a	P-*value*	I^{2 b} (%)	P^c _{heterogeneity}	Egger
Glycemic indices
FBG (mg/dl)	(4)	118	113	−1.86 (− 6.77, 3.06)	0.459	89.0	< 0.001	0.970
FI (pmol/L)	(4]	118	113	−0.10 (−0.72, 0.52)	0.752	81.1	0.001	0.275
Blood lipids
LDL-C (mg/dl)	(6)	155	156	−3.16 (−7.40, 1.09)	0.145	0.0	0.583	0.128
HDL-C (mg/dl)	(4)	109	111	0.41 (−2.27, 3.12)	0.763	0.0	0.775	0.200
TC (mg/dl)	(6)	155	156	−4.06 (−9.46, 1.34)	0.141	3.1	0.397	0.117
TG (mg/dl)	(4)	109	111	−4.92 (−19.59, 9.76)	0.512	31.5	0.223	0.610

FBG Fasting blood glucose, FI Fasting insulin, HDL-C High density cholesterol, HOMA-IR Homeostasis model assessment-estimated insulin resistance, LDL-C Low density cholesterol, TC Total cholesterol, TG Triglycerides
^aObtained from random effects model
^bInconsistency—percentage of variation across studies due to heterogeneity
^cObtained from fixed effects model

ISSN: 1476-511X